



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



June 03, 2020

| | |
|--|---|
| To BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001 | To National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051 |
| Security Code: 540596 | Symbol: ERIS |

Subject: Intimation of Incorporation of subsidiary Company

Dear Sir / Madam,

With reference to the captioned subject, we would like to inform you that the Company through its wholly owned Subsidiary Company namely Eris Healthcare Private Limited has incorporated a subsidiary company "Eris Pharmaceuticals Private Limited" on June 02, 2020.

The disclosure in terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular CIR/CFD/CMD/4/2015 September 09, 2015 is attached as 'Annexure A' .

You are requested to take the above clarification on record.

For Eris Lifesciences Limited

Milind Talegaonkar
Company Secretary & Compliance Officer

Encl: As above.

Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867

Annexure A

DISCLOSURE IN TERMS OF REGULATION 30 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 READ WITH SEBI CIRCULAR CIR/CFD/CMD/4/2015 SEPTEMBER 09, 2015 ARE AS UNDER:

| Sr. No. | Details of events required to be Disclosed | Disclosure |
|---------|---|--|
| 1 | Name of the target entity, details in brief such as size, turnover etc | Eris Pharmaceuticals Private Limited ("Eris Pharma") Authorized Share Capital: 10,00,000/- Paid-up Share Capital: 1,00,000/- Turnover: Nil (yet to commence business operations) |
| 2 | Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length" | The acquisition would NOT fall within related party transaction(s). Promoter/ Promoter Group/ Group Companies do not have any interest in the acquisition of Eris Pharma. |
| 3 | Industry to which the entity being acquired belongs | Pharmaceuticals |
| 4 | Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity) | Eris Pharma has been incorporated as a subsidiary of Eris Healthcare Private Limited [Wholly owned subsidiary of Eris Lifesciences Limited ("the Company")] for carrying out business related to pharmaceuticals products. |
| 5 | Brief details of any governmental or regulatory approvals required for the acquisition | No |
| 6 | Indicative time period for completion of the acquisition | NA |
| 7 | Nature of consideration - whether cash consideration or share swap and details of the same | Cash |
| 8 | Cost of acquisition or the price at which the shares are acquired | Rs. 76,000/- (7600 Equity shares of Rs. 10/- each) |
| 9 | Percentage of shareholding / control acquired and / or number of shares acquired | 76% |
| 10 | Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief) | Date of Incorporation: 02.06.2020 History of last 3 years: N.A. Country: India Focus Area: Manufacturing of Healthcare & OTC products. |